We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Variations Increase Heart Attack Risk for Statin Patients

By LabMedica International staff writers
Posted on 22 May 2018
Print article
Image: A diagram of the causes of coronary heart disease (Photo courtesy of US National Heart, Lung and Blood Institute).
Image: A diagram of the causes of coronary heart disease (Photo courtesy of US National Heart, Lung and Blood Institute).
Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of CHD, additional events occur despite statin therapy in some individuals.

Genetic variations have been discovered that increase the risk of heart attack even when patients are receiving a statin drug to lower their blood cholesterol. This may help to explain why some patients experience a heart attack or the need for coronary revascularization to open blocked heart arteries while taking statins. The discovery suggests that drugs targeting the genetic variations could lower the heart risk in these patients.

A large team of scientists led by those at Vanderbilt University Medical Center (Nashville, TN, USA) performed a two-stage genome-wide association study (GWAS) of CHD events during statin therapy. They first identified 3,099 cases that experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7,681 controls without CHD events during comparable intensity and duration of statin therapy. They then sought replication of candidate variants in another 160 cases and 1,112 controls performed a phenome-wide association study (PheWAS) for other traits linked to the most significant locus.

The investigators were able to identify seven genetic variations, called single nucleotide polymorphisms or SNPs, in the Lipoprotein(A) (LPA) locus of genes that were associated with these heart events in patients receiving statin treatment. The LPA gene encodes apolipoprotein (a), a fatty protein that binds to low-density lipoprotein (LDL), the form of blood cholesterol that is the target of statin drugs. High levels of bound LDL, called Lp(a) for short, is well known to be an independent risk factor for heart disease.

One of the SNPs was highly associated with an increased risk of heart events. When the team examined the full electronic health records (EHRs) of 11,566 individuals who carried the SNP for more than 1,000 physical conditions, they found significantly higher rates of coronary heart disease and heart attack but not of other diseases. Joshua C. Denny, MD, MS, a Professor of Biomedical Informatics and Medicine and a leading author of the study, said, “People with these genetic variants were at a higher risk for heart disease, even considering those who have ideal cholesterol levels on their statin.”

The authors concluded that a genetic variation at the LPA locus is associated with CHD events during statin therapy independent of the extent of LDL-C lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins. The study was published on April 27, 2018, in the journal Circulation.

Related Links:
Vanderbilt University Medical Center

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.